Search Results
Apr 06, 2026, 09:00 ET Abbott recebe aprovação regulatória no Brasil de serplulimabe, novo medicamento biológico para o tratamento de câncer de pulmão de pequenas células com doença extensa, oferecendo uma nova alternativa para pacientes
treatment for extensive-stage small-cell lung cancer: Efficacy and safety from the end-of-study analysis of the international phase 3 ASTRUM-005 study. J Clin Oncol 43, 8093-8093(2025). DOI: 10.1200/JCO.2025.43.16_suppl.8093.Instituto Nacional de Câncer – INCA: Câncer de pulmão. Acessado em março
More news about: Abbott
Apr 01, 2026, 23:59 ET 再鼎醫藥宣佈達成全球臨床研究合作及供應協議，以評估創新性DLL3抗體藥物偶聯物Zocilurtatug Pelitecan與雙特異性T細胞銜接器的聯合治療
2022.[3] Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561.[4]
More news about: 再鼎醫藥
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.htmlKato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679Forward-Looking StatementsThis press release
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 05:00 ET Resilience Care Expands to U.S. Market, Adds Veteran Digital Health Leaders to Support Growth with Oncology Providers
among healthcare professionals in Europe.[4] Basch, JCO 2016 ; Basch et al, JAMA 2022 ; Mir et al, Nat Med 2022 ; Patt, JCO Clin Informatics 2023.[5] Basch, JCO 2016.Logo:
More news about: Resilience Care
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
al. Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis. J Clin Lipidol. 2026.Shapiro MD. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving. Circulation.
More news about: Amgen
Mar 27, 2026, 09:23 ET « 10x10 » : les icônes d'Off-White™ réinventées ; 10 créatifs avant-gardistes du monde entier refaçonnent 10 icônes d'Off-White™
parisienne peu orthodoxe Pigalle, Stéphane a longtemps entretenu une relation profonde avec Virgil, qu'il exprime sur le blouson Varsity en faisant un clin d'œil à la fois aux motifs de l'héritage Off-White™ et à sa propre volonté de jouer.« HOODIES » par Yuta Hosokawa. Les créations du designer
More news about: Bluestar Alliance, LLC
Mar 26, 2026, 03:00 ET Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
Beauty Global Research. REF-145017. January 2026.Lipko-Godlewska S et al. Clin Cosmet InvestigDermatol.2021;14:169–178.Fakih N et al. Facial Plast Surg. 2022;38:173−176.Heydenrych I, et al. Clin Cosmet Investig Dermatol. 2021;14:779-814. Juvéderm® VOLITE®
More news about: AbbVie
Mar 24, 2026, 08:00 ET John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
YouTube.References Siegel RL, Wagle NS, Star J, et al. Colorectal cancer statistics, 2026. CA Cancer J Clin. 2026;e70067.Siegel RL, Wagle NS, Jemal A. "Leading Cancer Deaths in People Younger Than 50 Years." JAMA. Published Jan. 22, 2026.
More news about: Abbott
Mar 23, 2026, 14:26 ET Galderma reúne profissionais injetores para apresentar as últimas tendências em estética injetável
France. 12. Narins RS, et al. J Am Acad Dermatol. 2010 Mar;62(3):448-62. 13. Data on File. 14. Di Gregorio C et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690. 15. Talarico S et al. Dermatol Surg. 2015 Dec;41(12):1361-9. 16. Belmontesi M
More news about: Galderma
Mar 23, 2026, 09:00 ET Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing
1 Padala SK and Ellenbogen KA. Card Electrophysiol Clin. 2021;13(4):755-84.2 Vijayaraman
More news about: Medtronic plc
Mar 18, 2026, 09:00 ET Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases
Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research (Grant Number CLIN2-15547).
More news about: Aspen Neuroscience, Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia submissão regulatória suplementar de MINJUVI® (tafasitamabe) para linfoma folicular na Argentina e no México
2019;3(Suppl):85-87.Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la presentación regulatoria complementaria de MINJUVI® (tafasitamab) para linfoma folicular en Argentina y México
2019;3(Suppl):85-87.Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics Anuncia Aprovação de Indicação Adicional para MINJUVI® (tafasitamabe) no Brasil
2019;3(Suppl):85-87.Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la aprobación de una indicación adicional para MINJUVI® (tafasitamab) en Brasil
2019;3(Suppl):85-87.Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.Conconi A, Ponzio C, Lobetti-Bodoni C, et al. Incidence, risk factors and outcome of histological transformation in
More news about: Knight Therapeutics Inc.
Mar 16, 2026, 09:12 ET Royal Canin Renews Partnership with The University of Tennessee Veterinary Obesity Center
UTVOC's website. 1 Larsen JA, Villaverde C. Scope of the problem and perception by owners and veterinarians. Vet Clin North Am Small Anim Pract 2016; 46: 761-772.2 Salt C, et al. Association between life span and body condition in neutered
More news about: Royal Canin
Mar 13, 2026, 12:35 ET Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
doi:10.4103/0970-1591.16647510 Guancial EA, Roussel B, Bergsma DP, et al. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015;10:939-949.
More news about: Johnson & Johnson
Mar 12, 2026, 09:00 ET Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research. (Grant Numbers CLIN1-14300; CLIN2-19068).About Kenai TherapeuticsKenai Therapeutics is a clinical-stage biotechnology company pioneering next generation approaches
More news about: Kenai Therapeutics/BIOCOM
Mar 11, 2026, 07:00 ET BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
10):82–109.Ritchlin CT, et al. Ann Rheum Dis. 2023;82(11);1404–14.Felson DT, et al. Arthritis Rheum. 1995;38(6):727–35.Ogdie A, et al. Rheum Dis Clin North Am. 2015;41(4):545–68.About Psoriatic Arthritis. National Psoriasis Foundation.
More news about: UCB
Mar 10, 2026, 01:29 ET FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%
Ther. 2022;16:2803-2815. doi:10.2147/DDDT.S378813.Niazi SK. Support for removing pharmacodynamic and clinical efficacy testing of biosimilars. Clin Pharmacol Drug Dev. 2023;12(12):1134-1141. doi:10.1002/cpdd.1349.Niazi SK. Scientific justification and policy recommendations to the US FDA
More news about: Professor Sarfaraz K. Niazi
Mar 06, 2026, 15:10 ET CGTN : La Chine se prépare pour un démarrage solide de son prochain plan quinquennal et ouvre des perspectives au niveau mondial
rapport publié en janvier que l'avantage de la Chine en matière d'innovation technologique était renforcé par une « coordination centralisée », dans un clin d'œil aux vertus de sa planification.« Pékin traite l'IA comme une infrastructure », déclare le centre. « Grâce à une politique industrielle
More news about: CGTN
Mar 04, 2026, 10:50 ET Kelsey H. Collins, PhD, Wins NEXT Award for Translational Research on Relationship between Fat and Osteoarthritis Development and Pain
https://www.arthritis.org/diseases/osteoarthritis. Accessed Jan. 12, 2026.ii Hawker GA. 2019. Osteoarthritis is a serious disease. Clin Exp Rheumatol 37 Suppl 120:3-6.iii Griffin TM, Huebner JL, Kraus VB, Guilak F. Extreme obesity due to impaired leptin signaling
More news about: American Academy of Orthopaedic Surgeons
Mar 03, 2026, 16:01 ET Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.htmlKato, S. et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988-1997 doi: 10.1158/1078-0432.CCR-16-1679The American Cancer Society. Key Statistics for Acute Myeloid Leukemia (AML).
More news about: Rigel Pharmaceuticals, Inc.
Mar 03, 2026, 08:03 ET AMA Approves Category III CPT® Code for Innoblative's SIRA® RFA Electrosurgical Device, an Adjunct for Patients Undergoing Breast Conservation Surgery
Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.2Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci
More news about: Innoblative Designs, Inc.
Mar 01, 2026, 19:00 ET Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ASH Oral presentation #886Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437-1443. doi:10.1200/JCO.2016.70.2282Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol.
More news about: Innovent Biologics